Trials / Completed
CompletedNCT00140374
Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)
Phase I/II Study of Vaccination Priming and Vaccine Boosting With Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines in Patients With Prostate Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 36 (planned)
- Sponsor
- Cell Genesys · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and efficacy of priming vaccinations, and subsequent boosting vaccinations with GVAX® Vaccine for Prostate Cancer. Clinical observations and laboratory measurements will be monitored to evaluate safety and toxicity. Additionally, the antitumor effects of GVAX® Vaccine for Prostate Cancer on serum PSA levels, will be evaluated and antitumor responses will be quantitated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Immunotherapy allogeneic GM-CSF secreting cellular vaccine |
Timeline
- Start date
- 1998-12-01
- Completion
- 2001-02-01
- First posted
- 2005-09-01
- Last updated
- 2005-09-01
Source: ClinicalTrials.gov record NCT00140374. Inclusion in this directory is not an endorsement.